Pharmacokinetic profile of a single intramuscular or oral dose of meloxicam in red kangaroos (Osphranter rufus).

IF 1.3 3区 农林科学 Q2 VETERINARY SCIENCES
Ellis M Wright, Louden Wright, Sherry Cox, Heather Schwartz
{"title":"Pharmacokinetic profile of a single intramuscular or oral dose of meloxicam in red kangaroos (Osphranter rufus).","authors":"Ellis M Wright, Louden Wright, Sherry Cox, Heather Schwartz","doi":"10.2460/ajvr.24.10.0326","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Determine pharmacokinetic parameters of meloxicam in red kangaroos following a single IM or PO dose.</p><p><strong>Methods: </strong>In the spring of 2024, following a pilot study to determine the appropriate dosage, a managed population of clinically healthy adult or subadult red kangaroos at the Nashville Zoo received a 0.2-mg/kg dose of meloxicam, IM or PO. Four additional kangaroos received a 0.2-mg/kg dose of meloxicam, IV, to establish bioavailability. Blood samples were obtained under manual restraint over 48 hours, using a sparse sampling method. Plasma meloxicam concentration was determined using HPLC. Plasma meloxicam time-concentration profiles were established using a non-compartmental pharmacokinetic analysis.</p><p><strong>Results: </strong>15 kangaroos were included in this study. Eight kangaroos were assigned to the IM group, and 8 were assigned to the PO group. Pharmacokinetic parameters were time to the maximum observed plasma concentration (tmax) = 0.5 hours, maximum plasma concentration (Cmax) = 1.071 μg/mL, terminal half-life (t½) = 13.03 hours, elimination rate constant (λz) = 0.05 1/h, area under the plasma concentration-versus-time curve from time 0 to last point (AUC0-last) = 11.643 h·μg/mL, area under the plasma concentration-versus-time curve from time 0 to infinity (AUC0-∞) = 12.460 h·μg/mL, bioavailability = 129%, and apparent volume of distribution after extravascular administration (V/F) = 234 mL/kg, and tmax = 6 hours, Cmax = 0.445 μg/mL, t1/2 = 9.90 hours, λz = 0.07 1/h, AUC0-last = 6.666 h·μg/mL, AUC0-∞ = 7.023 h·μg/mL, bioavailability = 73%, and V/F = 557 mL/kg for the IM and PO groups, respectively. One kangaroo collapsed and died approximately 15 minutes following administration of an IV dose of meloxicam. Necropsy revealed intracranial hemorrhage.</p><p><strong>Conclusions: </strong>The Cmax and t1/2 of meloxicam were greater in the IM group than the PO group. When dosed IM, plasma meloxicam concentrations reached levels reported to be therapeutic in other species, while this was inconsistently achieved with PO dosing.</p><p><strong>Clinical relevance: </strong>IM meloxicam may offer advantages to PO dosing due to the greater Cmax and longer t1/2. Nonsteroidal anti-inflammatory drugs are known to decrease platelet function, and it is unknown if red kangaroos are at increased risk for hemorrhage following the administration of meloxicam compared to other species.</p>","PeriodicalId":7754,"journal":{"name":"American journal of veterinary research","volume":" ","pages":"1-7"},"PeriodicalIF":1.3000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of veterinary research","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.2460/ajvr.24.10.0326","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Determine pharmacokinetic parameters of meloxicam in red kangaroos following a single IM or PO dose.

Methods: In the spring of 2024, following a pilot study to determine the appropriate dosage, a managed population of clinically healthy adult or subadult red kangaroos at the Nashville Zoo received a 0.2-mg/kg dose of meloxicam, IM or PO. Four additional kangaroos received a 0.2-mg/kg dose of meloxicam, IV, to establish bioavailability. Blood samples were obtained under manual restraint over 48 hours, using a sparse sampling method. Plasma meloxicam concentration was determined using HPLC. Plasma meloxicam time-concentration profiles were established using a non-compartmental pharmacokinetic analysis.

Results: 15 kangaroos were included in this study. Eight kangaroos were assigned to the IM group, and 8 were assigned to the PO group. Pharmacokinetic parameters were time to the maximum observed plasma concentration (tmax) = 0.5 hours, maximum plasma concentration (Cmax) = 1.071 μg/mL, terminal half-life (t½) = 13.03 hours, elimination rate constant (λz) = 0.05 1/h, area under the plasma concentration-versus-time curve from time 0 to last point (AUC0-last) = 11.643 h·μg/mL, area under the plasma concentration-versus-time curve from time 0 to infinity (AUC0-∞) = 12.460 h·μg/mL, bioavailability = 129%, and apparent volume of distribution after extravascular administration (V/F) = 234 mL/kg, and tmax = 6 hours, Cmax = 0.445 μg/mL, t1/2 = 9.90 hours, λz = 0.07 1/h, AUC0-last = 6.666 h·μg/mL, AUC0-∞ = 7.023 h·μg/mL, bioavailability = 73%, and V/F = 557 mL/kg for the IM and PO groups, respectively. One kangaroo collapsed and died approximately 15 minutes following administration of an IV dose of meloxicam. Necropsy revealed intracranial hemorrhage.

Conclusions: The Cmax and t1/2 of meloxicam were greater in the IM group than the PO group. When dosed IM, plasma meloxicam concentrations reached levels reported to be therapeutic in other species, while this was inconsistently achieved with PO dosing.

Clinical relevance: IM meloxicam may offer advantages to PO dosing due to the greater Cmax and longer t1/2. Nonsteroidal anti-inflammatory drugs are known to decrease platelet function, and it is unknown if red kangaroos are at increased risk for hemorrhage following the administration of meloxicam compared to other species.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
10.00%
发文量
186
审稿时长
3 months
期刊介绍: The American Journal of Veterinary Research supports the collaborative exchange of information between researchers and clinicians by publishing novel research findings that bridge the gulf between basic research and clinical practice or that help to translate laboratory research and preclinical studies to the development of clinical trials and clinical practice. The journal welcomes submission of high-quality original studies and review articles in a wide range of scientific fields, including anatomy, anesthesiology, animal welfare, behavior, epidemiology, genetics, heredity, infectious disease, molecular biology, oncology, pharmacology, pathogenic mechanisms, physiology, surgery, theriogenology, toxicology, and vaccinology. Species of interest include production animals, companion animals, equids, exotic animals, birds, reptiles, and wild and marine animals. Reports of laboratory animal studies and studies involving the use of animals as experimental models of human diseases are considered only when the study results are of demonstrable benefit to the species used in the research or to another species of veterinary interest. Other fields of interest or animals species are not necessarily excluded from consideration, but such reports must focus on novel research findings. Submitted papers must make an original and substantial contribution to the veterinary medicine knowledge base; preliminary studies are not appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信